SBIR/STTR Research Award
Therapeutic Antibody Discovery from Pancreatic Cancer B Cell Repertoires
Award amount
$217,469Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Gigagen, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- HF7MJJDVQQX5
- Solicitation number
- PA14-071
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): The Specific Aim of this SBIR Phase I project is to build a technology for discovery of monoclonal antibody (mAb) drug candidates for pancreatic cancer from rare primary B cells. Pancreatic cancer has proven resilient to drugs that target oncology's usual suspects , including proteins related to angiogenesis, proliferation, and metastasis (Mackenzie and McCollum, 2009). mAbs are therapeutic agents of choice for oncology (Gura, 2002; Elder, 2011). Traditionally, mAb discovery programs identify a lead target antigen and screen antibody libraries for affinity using either phage display or mouse hybridomas. As an alternative, some academic and industry groups have been using human B cell hybridomas (Lang et al., 1990; Yu etal., 2008) to mine natural repertoires for candidate therapeutic antibodies. B cell hybridomas are technically challenging and inefficient, but natural antibodies have several advantages, including low immunogenicity, in vivo affinity maturation, and excelle
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Production Technology for Recombinant Intravenous Immunoglobulin
- Next-Generation Antibody Discovery and Development Technology
- Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency
- Recombinant Hyperimmune Gammaglobulin for Pneumococcal Disease
- Production Technology for Recombinant Intravenous Immunoglobulin
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
17 SBIR/STTR records share this UEI (2011–2017). Reported award amounts total $10,857,672. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation, Department of Energy